The Tyrosine Kinase Inhibitor Lenvatinib Inhibits Anaplastic Thyroid Carcinoma Growth by Targeting Pericytes in the Tumor Microenvironment
Thyroid® · 2023
DOI: 10.1089/thy.2022.0597 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thyroid®, 2023. Verfasst von Asumi Iesato und 6 weiteren Autor:innen. Beteiligte Einrichtung: Human Thyroid Cancers Preclinical and Translational Research Program, Division of Experimental Pathology, Cancer Research Institute (CRI), Cancer Cen…. Hauptthemen laut MEDLINE: Thyroid Carcinoma, Anaplastic, Thyroid Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Human Thyroid Cancers Preclinical and Translational Research Program, Division of Experimental Pathology, Cancer Research Institute (CRI), Cancer Center, Department of Pathology, Beth Israel Deaconess Medical Center, Ha…
- Center for Vascular Biology Research (CVBR), Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
- Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
- Musculoskeletal Translational Innovation Initiative, Department of Orthopedic Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
- Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
ORCID-Profile: Peter M Sadow
Förderung
- NCI NIH HHS
Zitieren
APA
Iesato, A., Li, S., Sadow, P. M., Abbasian, M., Nazarian, A., Lawler, J., & Nucera, C. (2023). The Tyrosine Kinase Inhibitor Lenvatinib Inhibits Anaplastic Thyroid Carcinoma Growth by Targeting Pericytes in the Tumor Microenvironment. Thyroid®. https://doi.org/10.1089/thy.2022.0597
Vancouver
Iesato A, Li S, Sadow PM, Abbasian M, Nazarian A, Lawler J, et al. The Tyrosine Kinase Inhibitor Lenvatinib Inhibits Anaplastic Thyroid Carcinoma Growth by Targeting Pericytes in the Tumor Microenvironment. Thyroid®. 2023. doi:10.1089/thy.2022.0597
BibTeX
@article{Iesato2023,
author = {Iesato, Asumi and Li, Stephanie and Sadow, Peter M and Abbasian, Mohammadreza and Nazarian, Ara and Lawler, Jack and Nucera, Carmelo},
title = {The Tyrosine Kinase Inhibitor Lenvatinib Inhibits Anaplastic Thyroid Carcinoma Growth by Targeting Pericytes in the Tumor Microenvironment},
journal = {Thyroid®},
year = {2023},
doi = {10.1089/thy.2022.0597}
}
EUVIMED